Even in Denmark — Novo Nordisk's residence marketplace — an application for Wegovy to obtain public health and fitness insurance coverage was rejected over the grounds that its cost was incommensurate with its therapeutic worth.When the drug is discovered to have wider-reaching purposes, together with cardiovascular Added benefits, it is more m